

PRESS RELEASE

OCTOBER 4, 2024

NANOLOGICA RECEIVES SUPPLEMENTARY ORDER WORTH APPROXIMATELY SEK 1.9 MILLION FROM RETURNING CUSTOMER IN CHINA

Nanologica has received a supplementary order for the company's silica-based purification media NLAB Saga® from the customer in China who at the end of September placed an order for NLAB Saga® at a value of approximately SEK 3.7 million. The value of this supplementary order amounts to approximately SEK 1.9 million.

The customer is a pharmaceutical manufacturer that primarily produces peptides including GLP-1 analogues. In June this year, they placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today's order is the third order for NLAB Saga® from the customer.

"The fact that the customer increases the order they placed last week indicates that they are satisfied with the product and have strong confidence that it meets their needs. We look forward to continued good cooperation with this customer. I would also like to pay tribute to our team who have been working intensively with customers in the Chinese market since the beginning of this year, and it is very satisfying to now see that work bear fruit", CEO Andreas Bhagwani comments.

For further information, please contact:

Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Thanks to their efficient and long-lasting purification, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of an increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective medicines through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-04 13:55 CEST.